1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSignios bio Xenium 5K Spatial Transcriptomics grant program is sponsored by Signios Bio (in collaboration with 10x Genomics). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Signios bio Xenium 5k Spatial transcriptomics grant program - Signios Bio Xenium 5K Spatial Transcriptomics Grant Program Signios Bio is pleased to announce a new grant program leveraging the power of 10x Genomics Xenium 5K Spatial Transcriptomics Signios Biosciences (“Signios Bio”), a science-first biotechnology company offering multiomics services, in collaboration with 10x Genomics , is offering a Signios-sponsored grant for the Xenium 5K Spatial Transcriptomics platform.
This high-plex, imaging-based spatial technology enables targeted, single-cell-resolution gene expression profiling directly in human and mouse tissue sections.
The Xenium 5K Panel enables the simultaneous detection of up to 5,000 RNA targets per sample while preserving spatial context, allowing researchers to study cell-type localization, cell–cell interactions, biomarker expression, and pathway activity within intact tissue architecture. The platform supports FFPE and fresh-frozen tissues and delivers high-resolution gene expression maps at scale.
Signios Bio and 10x Genomics will work closely with the awardees to support experimental execution, data analysis, and publication efforts. Following completion of the study, award recipients will have the opportunity to present their findings at upcoming Signios/10x Genomics scientific events.
Grant Opportunity: What We’re Offering We aim to support innovative spatial transcriptomics projects by awarding grants to top proposals using the Xenium 5K platform. The grant will cover the cost of Xenium processing and analysis for two Xenium 5K slides, with full access to Signios Bio’s expertise in workflow support, data generation, and analysis.
A total of six awards will be granted across three categories: First Place Grant Recipient (1 grant winner): Priority access to a Xenium 5K run in our lab in Foster City, CA Full-service spatial transcriptomics, including sectioning, sample placement on two Xenium 5K slides, imaging, and data processing Support for data analysis and quality control by our bioinformatics team Second Place (2 grant winners): 50% off ($30k value) – total service cost $15K Xenium 5K run, two slides, in our lab in Foster City, CA Full-service spatial transcriptomics, including sectioning, sample placement on two Xenium 5K slides, imaging, and data processing Support for data analysis and quality control via our bioinformatics team Third Place (3 grant winners): 30% off ($30k value) – total service cost $21k Xenium 5K run, two slides, in our lab in Foster City, CA Full-service spatial transcriptomics, including sectioning, sample placement on two Xenium 5K slides, imaging, and data processing Support for data analysis and quality control via our bioinformatics team Who Should Apply and What Project Types?
This grant program is open only to U.S.- based applicants.
Eligible applicants include: Biotech or pharmaceutical scientists Researchers studying human or mouse tissues A clear biological hypothesis amenable to spatial transcriptomics (e.g., tumor microenvironment, tissue architecture, cellular heterogeneity, biomarker localization) A need for high-plex RNA profiling with single-cell spatial resolution, particularly for focused gene sets or pathway-level analyses Submit a brief abstract describing: Rationale for using spatial transcriptomics / Xenium 5K Sample type (human/mouse, tissue type, FFPE or frozen) and number of samples Expected impact or significance of results If selected, when will your samples be ready for submission, or will they still need to be collected?
Interested in other genomic or multiomic approaches? Learn more about Signios Bio’s full range of certified genomics services and how we support research across diverse applications. Explore our services [ Certified Genomics Service Provider | Signios Bio ] Signios Biosciences, (formerly named MedGenome US Research) is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data.
By combining cutting-edge AI, multiomic technologies, and scientific partnership, Signios Bio enables the discovery and development of next-generation therapies and diagnostics that are more inclusive, effective, and transformative.
According to the current listing, eligibility includes: Academic researchers, biotech or pharmaceutical scientists, and researchers studying human or mouse tissues. Open only to U. S. -based applicants. Confirm the full requirements in the official notice before applying.
Signios bio Xenium 5K Spatial Transcriptomics grant program is funded by Signios Bio (in collaboration with 10x Genomics). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NSF 26-517 replaces the core solicitations of Environmental Biology, Integrative Organismal Systems and Molecular and Cellular Biosciences with a single directorate-wide opportunity. Proposals are accepted anytime, sorted centrally by NSF rather than targeted by the PI, and reorganized under three inquiry areas. Here is what the $280 million actually buys, why the loss of program targeting cuts both ways, and what to do before the September 16 webinar.
Read articleWith Forms J in FY2027, NIH will no longer accept letters of support — the boilerplate endorsements applicants have padded proposals with for decades. Notice NOT-OD-26-094 replaces them with letters of collaboration, aligning NIH with NSF. Here is exactly what changes, what a compliant letter must now contain, who can no longer write one, and how this fits the broader re-engineering of the NIH application package.
Read articleOMB and roughly 40 agencies have proposed the most sweeping overhaul of 2 CFR Part 200 in more than a decade. Political appointees would pre-review notices of funding opportunity and discretionary awards, agencies gain near-unappealable 'national interest' termination authority, and federal funds can no longer support collaborations with covered foreign entities. The rule drew nearly half a million comments and is slated to take effect October 1, 2026. Here is what actually changes, who is exposed, and how to write proposals that survive the new regime.
Read article